Sophia Ran

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi request reprint Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy
    Sophia Ran
    Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390 8594, USA
    Int J Radiat Oncol Biol Phys 54:1479-84. 2002
  2. pmc Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells
    Emely Castro-Rivera
    Departments of Internal Medicine, Hamon Center for Therapeutic Oncology Research Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    Cancer Res 68:8295-303. 2008
  3. pmc The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors
    Sophia Ran
    Simmons Comprehensive Cancer Center and Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Neoplasia 7:486-96. 2005
  4. ncbi request reprint Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice
    Sophia Ran
    Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, 2201 Inwood Road NC7 304, Dallas, TX 75390, USA
    Clin Cancer Res 11:1551-62. 2005
  5. pmc Tumor oxygen dynamics: correlation of in vivo MRI with histological findings
    Dawen Zhao
    Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA
    Neoplasia 5:308-18. 2003
  6. ncbi request reprint Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction
    Ralph P Mason
    Department of Radiology, U T Southwestern Medical Center, Dallas, TX 75390, USA
    Adv Exp Med Biol 530:197-204. 2003
  7. pmc Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy
    Sophia Ran
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8594, USA
    Neoplasia 5:297-307. 2003
  8. ncbi request reprint Increased exposure of anionic phospholipids on the surface of tumor blood vessels
    Sophia Ran
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas 75390 8594, USA
    Cancer Res 62:6132-40. 2002
  9. ncbi request reprint Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology
    Ralph P Mason
    Department of Radiology, U T Southwestern Medical Center, Dallas, Texas, USA
    J Cell Biochem Suppl 39:45-53. 2002
  10. pmc Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect
    Emely Castro-Rivera
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 101:11432-7. 2004

Collaborators

  • Wei Zhang
  • Khalid A Mohamedali
  • P E Thorpe
  • R P Mason
  • Dawen Zhao
  • M G Rosenblum
  • Emely Castro-Rivera
  • Lisa D Volk
  • Michael J Flister
  • Rolf A Brekken
  • Christopher M Bivens
  • Brandt Whitehurst
  • John D Minna
  • Sucharita Bandyopadhyay
  • Liesbeth M Veenendaal
  • Alan Stutzman
  • Neil Desai
  • Vuong Trieu
  • Lisa Volk
  • Juhi Bagaitkar
  • Brent Pickett
  • Robert D Gerard
  • Misako Watabe
  • David Piquemal
  • Kounosuke Watabe
  • Yukio Takano
  • Shigeru Hirota
  • Sadahiro Hosobe
  • Sudha K Pai
  • Therese Commes
  • Steven C Gross
  • Ken Saito
  • Ying Wang
  • Hangqing Jin
  • Lawrence Cheung
  • Johannes Waltenberger
  • Nora Navone
  • John W Marks

Detail Information

Publications15

  1. ncbi request reprint Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy
    Sophia Ran
    Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390 8594, USA
    Int J Radiat Oncol Biol Phys 54:1479-84. 2002
    ..2) To determine whether PS exposure can be induced on viable endothelial cells in tissue culture by conditions present in the tumor microenvironment...
  2. pmc Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells
    Emely Castro-Rivera
    Departments of Internal Medicine, Hamon Center for Therapeutic Oncology Research Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    Cancer Res 68:8295-303. 2008
    ..We conclude that SEMA3B is a potential tumor suppressor that induces apoptosis in SEMA3B-inactivated tumor cells through the Np-1 receptor by inactivating the Akt signaling pathway. CA118384..
  3. pmc The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors
    Sophia Ran
    Simmons Comprehensive Cancer Center and Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Neoplasia 7:486-96. 2005
    ..Thus, the antitumor vascular-ablative effect of VEGF(121)/rGel may be utilized not only for treating primary tumors but also for inhibiting metastatic spread and vascularization of metastases...
  4. ncbi request reprint Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice
    Sophia Ran
    Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, 2201 Inwood Road NC7 304, Dallas, TX 75390, USA
    Clin Cancer Res 11:1551-62. 2005
    ..In the present study, we tested the hypothesis that a monoclonal antibody directed against anionic phospholipids might exert antitumor effects by causing vascular damage in tumors...
  5. pmc Tumor oxygen dynamics: correlation of in vivo MRI with histological findings
    Dawen Zhao
    Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA
    Neoplasia 5:308-18. 2003
    ..These results further validate the utilization of FREDOM to monitor tumor oxygenation and concur with the hypothesis that the level of hypoxia is related to tumor growth rate and poor vascularity...
  6. ncbi request reprint Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction
    Ralph P Mason
    Department of Radiology, U T Southwestern Medical Center, Dallas, TX 75390, USA
    Adv Exp Med Biol 530:197-204. 2003
    ..This has allowed us both to investigate dynamic response to respiratory challenge (carbogen) and to probe the mechanisms of a new anti-vascular therapy designed to produce tumor-specific infarction...
  7. pmc Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy
    Sophia Ran
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8594, USA
    Neoplasia 5:297-307. 2003
    ..Vascular damage was not observed in normal organs, including kidneys and pancreas. These studies demonstrate that anti-VEGFR2 antibodies have potential for vascular targeting and imaging of tumors in vivo...
  8. ncbi request reprint Increased exposure of anionic phospholipids on the surface of tumor blood vessels
    Sophia Ran
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas 75390 8594, USA
    Cancer Res 62:6132-40. 2002
    ..Anionic phospholipids on tumor vessels could potentially provide markers for tumor vessel targeting and imaging...
  9. ncbi request reprint Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology
    Ralph P Mason
    Department of Radiology, U T Southwestern Medical Center, Dallas, Texas, USA
    J Cell Biochem Suppl 39:45-53. 2002
    ....
  10. pmc Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect
    Emely Castro-Rivera
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 101:11432-7. 2004
    ..In conclusion, we hypothesize that VEGF165, produced by tumor cells, acts as an autocrine survival factor and that SEMA3B mediates its tumor-suppressing effects, at least in part, by blocking this VEGF autocrine activity...
  11. ncbi request reprint A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model
    Wei Zhang
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8594, USA
    Angiogenesis 5:35-44. 2002
    ..These findings suggest that 2C3 is a candidate for treating primary cancer and for preventing the outgrowth of tumor metastases in cancer patients...
  12. ncbi request reprint Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression
    Sucharita Bandyopadhyay
    Department of Medical Microbiology and Immunology, Southern Illinois University School of Medicine, Springfield, IL 62702, USA
    Oncogene 23:5675-81. 2004
    ..Together, our results strongly suggest functional involvement of the Drg-1 gene in suppressing the metastatic advancement of human breast cancer...
  13. ncbi request reprint Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model
    Brandt Whitehurst
    Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL, USA
    Int J Cancer 121:2181-91. 2007
    ..These results suggest a novel mechanism by which anti-VEGF-A therapy may suppress tumor lymphangiogenesis and subsequent metastasis supporting the use of anti-VEGF-A therapy to control metastasis clinically...
  14. pmc Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy
    Lisa D Volk
    Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, 801 N Rutledge, Springfield, IL, 62794 9678, USA
    Neoplasia 10:613-23. 2008
    ..The significant increase in the cure of tumor-bearing mice in the nab-paclitaxel/bevacizumab combined group compared with mice treated with single drugs strongly advocates for implementing such strategy in clinics...
  15. pmc In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors
    Liesbeth M Veenendaal
    Immunopharmacology and Targeted Therapy Section, Department of Bioimmunotherapy, Univ of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Proc Natl Acad Sci U S A 99:7866-71. 2002
    ..These studies demonstrate the successful use of VEGF(121)/rGel fusion construct for the targeted destruction of tumor vasculature in vivo...